Cytokinetics (CYTK) Misses Q3 EPS by 13c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $75.87 +2.35%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- Wendy's U.S. president to resign, company to create COO role
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
